Last reviewed · How we verify
NCT05703633: REVIVEME
Transplantation of Uncontrolled DCD Kidneys REconditioned by a Novel Ex-VIVo Perfusion MEthod
Phase 1, PHASE2 trial testing uDCD treatment in End-Stage Kidney Disease in 8 participants. Status unknown.
31 August 2024
Quick facts
| Lead sponsor | Sahlgrenska University Hospital |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 8 |
| Start date | 21 August 2023 |
| Primary completion | 31 August 2024 |
| Estimated completion | 31 December 2024 |
Drugs / interventions tested
- uDCD treatment
Conditions studied
- End-Stage Kidney Disease — all drugs for End-Stage Kidney Disease →
Sponsor
Sahlgrenska University Hospital
Who can join
Adults 18 to 65, any sex, with End-Stage Kidney Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Eight patient will be transplanted with kidneys from donors dying after uncontrolled circulatory arrest (uDCD), with prolonged warm ischemia (up to 4,5 hours), preserved by a new method based on removal of fibrinogen/fibrin in the capillary systems, leading to an effective oxygenation of the tissue using an ex-vivo hospital manufactured perfusion device, minimizing the risk for ischemia-reperfusion injury (I/R-I) after kidney transplantation.Each patient will be studied for three months, with long-term follow-up data collected at 6 and 12 months
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05703633
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for End-Stage Kidney Disease
Currently open trials in the same condition.
- NCT06700876 — Evaluation of IGRA, Symptoms and Chest Radiograph for Subclinical TB Detection in ESRD and KT · recruiting
- NCT05931276 — CSP #2026 - Beta Blocker Dialyzability on Cardiovascular Outcomes · Phase 3 · recruiting
- NCT04646226 — The Arteriovenous Vascular (AV) ACCESS Trial · NA · active not recruiting
- NCT05449067 — Comparison of Efficacy Between Nighttime and Daytime Peritoneal Dialysis · NA · recruiting
Other Sahlgrenska University Hospital trials
Trials by the same sponsor.
- NCT07491094 — Repeated Examinations for Typing Pulmonary Embolism · recruiting
- NCT07524608 — Implementing an Evidence-based, Standardized Care Bundle Targeting Register Nurses and Anaesthesiologists, to Enhance Pa · not yet recruiting
- NCT07498959 — Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer · NA · recruiting
- NCT06896578 — Latitude - Lateral Lymph Node Attitude Study · NA · not yet recruiting
- NCT07035600 — Walking and Sitting Difficulties After Rectal Cancer Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05703633 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sahlgrenska University Hospital
- Last refreshed: 31 January 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05703633.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing